Xilio Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
XLO Nasdaq 8731 https://xiliotx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Xilio Therapeutics Inc

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors - May 25th, 2023 9:01 pm
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results - May 9th, 2023 11:30 am
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 3rd, 2023 8:05 pm
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results - Mar 2nd, 2023 9:05 pm
Xilio Therapeutics to Present at Upcoming Investor Conferences - Feb 27th, 2023 12:30 pm
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit - Feb 16th, 2023 12:30 pm
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day - Feb 2nd, 2023 12:30 pm
Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most - Jan 26th, 2023 10:30 am
These 2 ‘Strong Buy’ Penny Stocks Are on Track for Massive Gains, Say Analysts - Jan 25th, 2023 2:45 pm
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12 - Nov 23rd, 2022 12:30 pm
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results - Nov 9th, 2022 12:30 pm
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit - Nov 4th, 2022 11:30 am
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference - Sep 22nd, 2022 8:05 pm
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors - Sep 15th, 2022 8:05 pm
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference - Sep 6th, 2022 8:05 pm
Is Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth? - Aug 11th, 2022 1:41 pm
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results - Aug 9th, 2022 11:30 am
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President - Jun 16th, 2022 11:30 am